Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zandatrigine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A known ✓ | Q9UQD0 | 20/20 | 1.00 |
| ▸ | SCN1A | P35498 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zandatrigine SCHEMBL19612884 | 1.00 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL29565056 | 1.00 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19612883 | 1.00 | SCN8A (1.00) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19613789 | 0.96 | SCN8A (0.93) | SCN8ASCN1A | |
| Zandatrigine SCHEMBL19613790 | 0.96 | SCN8A (0.93) | SCN8ASCN1A | |
| SCHEMBL19612903 | 0.94 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612902 | 0.94 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612896 | 0.93 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19612895 | 0.93 | SCN8A (1.00) | SCN8ASCN1A | |
| SCHEMBL19613045 | 0.92 | SCN8A (1.00) | SCN8ASCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458449-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2025-03-05 | — | — | EP | claimed |
| US-20230404913-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-21 | — | — | US | claimed |
| US-20230405023-A1 | USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER (S)-4-((1-BENZYLPYRROLIDIN-3-YL)(METHYL)AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL)BENZENESULFONAMIDE, TOGETHER WITH STRONG INDUCERS OF CYTOCHROME P450 3A4, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAVI.6 ACTIVITY | XENON PHARMACEUTICALS INC. (CA) | 2023-12-21 | — | — | US | claimed |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2022-04-12 | — | — | US | claimed |
| CN-109526219-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2021-03-12 | — | — | CN | claimed |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-11-12 | — | — | US | claimed |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2020-10-27 | — | — | US | claimed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | claimed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | claimed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | claimed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | claimed |
| US-20250333404-A1 | DEUTERATED COMPOUNDS | NEUROCRINE BIOSCIENCES INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-3458449-B1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025024795-A1 | CRYSTALLINE FORMS | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20230404913-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | XENON PHARMACEUTICALS INC. (CA) | 2023-12-21 | — | — | US | disclosed |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2019-04-02 | — | — | US | disclosed |
| EP-3458449-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2019-03-27 | — | — | EP | disclosed |
| WO-2017201468-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | WO | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250333404-A1 | DEUTERATED COMPOUNDS | KCNN3, SCN1B, SCNN1B | SCN8A 21/4885SCN1A 8/4885 |
| US-10815229-B1 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885 |
| US-10246453-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885 |
| US-20230405023-A1 | USE OF THE NAV1.6 SODIUM CHANNEL BLOCKER (S)-4-((1-BENZYLPYRROLIDIN-3-YL)(METHYL)AMINO)-2-FLUORO-5-METHYL-N(THIAZOL-4-YL)BENZENESULFONAMIDE, TOGETHER WITH STRONG INDUCERS OF CYTOCHROME P450 3A4, IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH NAVI.6 ACTIVITY | SCN4A, SCN1B, SCN1A | SCN8A 15/4885SCN1A 3/4885 |
| US-11299490-B2 | Benzenesulfonamide compounds and their use as therapeutic agents | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885 |
| US-20170334902-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885 |
| US-20200354354-A1 | BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN1B, SCN2B | SCN8A 14/4885SCN1A 1/4885 |
| US-20230404913-A1 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES ASSOCIATED WITH VOLTAGE-GATED SODIUM CHANNELS | SCN4A, SCN5A, KCNJ4 | SCN8A 6/4885SCN1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.